

ARTICLE OPEN



Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

Inge LeFevre^{1,9}, Lulu Bravo^{2,9}, Nicolas Folschweiller¹, Eduardo Lopez Medina³, Edson Duarte Moreira Jr⁴, Francesco Nordio⁵, Mayuri Sharma⁵, Leslie M. Tharenos⁶, Vianney Tricou¹, Veerachai Watanaveeradej⁷, Peter J. Winkle⁸ and Shibadas Biswal^{5✉}

Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines. Dengue, caused by a mosquito-transmitted flavivirus endemic to many tropical and subtropical regions, is traditionally thought of as a pediatric disease but is now a global threat to both children and adults. We bridged immunogenicity data from a phase 3 efficacy study of a tetravalent dengue vaccine (TAK-003), performed in children and adolescents living in endemic areas, with an immunogenicity study in adults in non-endemic areas. Neutralizing antibody responses were comparable in both studies following receipt of a two-dose TAK-003 schedule (months 0 and 3). Similar immune responses were observed across exploratory assessments of additional humoral responses. These data support the potential for clinical efficacy of TAK-003 in adults.

npj Vaccines (2023)8:75; <https://doi.org/10.1038/s41541-023-00670-6>

INTRODUCTION

While large-scale, placebo-controlled efficacy studies remain the gold standard for evaluating vaccine performance before approval for use in the general population, studies in the entire intended target population are not always achievable. For example, large-scale efficacy trials are challenging to perform, perhaps because the disease is rare overall or in a certain target age group, as the number of participants who would need to be enrolled to allow statistical evaluation of the findings is unfeasibly large¹. Additionally, factors such as the need for rapid development of vaccines (such as during a pandemic situation) may mean that there is limited time to perform efficacy evaluation in target populations who were excluded from early-phase studies (e.g., children and adolescents)².

Once vaccine efficacy has been established under one set of conditions, immunobridging is a methodology that can be used to infer efficacy in another set of conditions, such as evaluating a different age group, different formulation, or different dosing regimen^{3–5}. Immunobridging has been successfully used in the development of a number of vaccines, including 20-valent pneumococcal vaccine⁶, COVID-19⁷, and human papillomavirus (HPV)⁸. For pneumococcal conjugate vaccines (PCVs), and despite the existence of aggregate correlate of protection (CoP), this strategy was used to translate immunogenicity data from a new-generation vaccine with increased valence, from a different age group, or from a vaccine made by a different manufacturer. Likelihood of protection against pneumococcal diseases and nasopharyngeal carriage based on immunobridging to an early PCV, which was initially licensed in infants and toddlers on basis of efficacy trial data^{9–11}, has been accepted by national regulatory authorities^{12,13}, especially when there was the commitment to generate direct evidence of effectiveness in post-licensure studies^{14,15}. The same strategy was applied for a new-generation

COVID-19 vaccine when conducting efficacy trials became unethical or impractical⁷. For the HPV vaccines, immunobridging was used to support their use in girls aged 9–15 years, assuming that efficacy was comparable if the antibody responses were non-inferior in young women aged 16–26 years, among whom clinical efficacy against a surrogate endpoint for cervical cancer was demonstrated^{16,17}. Immunobridging based on demonstrating non-inferiority of the immune responses was also used to support the further extension of the indications to include use in women aged 27–45 years and in boys and men aged from 9–47 years (supported by demonstrated efficacy against genital warts and a surrogate endpoint for anal cancer in men aged 16–26 years), to facilitate clinical development of a 9-valent HPV vaccine, and to support a dose-schedule reduction (from 3 to 2 doses)^{18–23}.

While half of the world's population is estimated to live in areas at risk of infection with dengue viruses (DENVs), the majority of cases occur in children and adolescents²⁴. However, in some areas, such as Thailand, the mean age of DENV infection is increasing, with approximately 30–40% of cases occurring in adults²⁵. Additionally, dengue poses a significant risk to international travelers, accounting for more febrile illness cases in returning travelers from South-East Asia than malaria²⁶. While traditionally considered a pediatric disease, adults experience a substantial burden of dengue, meaning that evaluation of potential vaccine performance in this population remains important. Furthermore, comorbidities such as diabetes, cardiovascular disease, renal impairment, and respiratory disease, which are much more prevalent in adults than children, have been identified as significant risk factors for developing severe dengue^{27,28}. In dengue-endemic areas, a significant proportion of the population has experienced at least one DENV infection early in life. This limited number of dengue-naïve individuals, which is arguably the most important population from the point of a dengue vaccine development, precludes conducting an efficacy study in adults

¹Vaccines Business Unit, Takeda Pharmaceuticals International AG, Zürich, Switzerland. ²College of Medicine, University of the Philippines, Manila, Philippines. ³Centro de Estudios en Infectología Pediátrica CEIP; Department of Pediatrics, Universidad Del Valle; Clínica Imbanaco, Grupo Quironsalud, Cali, Colombia. ⁴Associação Obras Sociais Irmã Dulce Hospital Santo Antônio and Oswaldo Cruz Foundation, Bahia, Brazil. ⁵Takeda Vaccines, Inc., Cambridge, MA, USA. ⁶The Division of Environmental and Occupational Health Sciences, University of Illinois at Chicago School of Public Health, Chicago, IL, USA. ⁷Department of Pediatrics, Phramongkutkiao Hospital and Faculty of Medicine, Kasetsart University, Bangkok, Thailand. ⁸Anaheim Clinical Trials, Anaheim, CA, USA. ⁹These authors contributed equally: Inge LeFevre, Lulu Bravo. [✉]email: shibadas.biswal@takeda.com

living in endemic areas²⁹, and the lack of CoP means that antibody titers cannot be directly translated in an estimate of protection from dengue. In addition, infection with DENV results in type-specific and both transient and longer-lasting heterotypic antibodies³⁰, presenting additional challenges both for evaluating dengue vaccine performance outside of an efficacy study and establishing a CoP. Immunobridging between children/adolescents and adult populations has been performed for the only currently licensed tetravalent dengue vaccine, CYD-TDV, with expected vaccine efficacy higher in adults and in recipients who had previously been exposed to DENV^{31,32}.

Given the limitations of robustly assessing dengue vaccine efficacy in adults, we performed immunobridging between immunogenicity data obtained in the large-scale, placebo-controlled efficacy study of the tetravalent dengue vaccine TAK-003, performed in children and adolescents aged 4–16 years living in dengue-endemic regions of Asia and Latin America (DEN-301; NCT02747927), and a phase 3 study in adults aged 18–60 years living in regions of the United States considered non-endemic for dengue (DEN-304; NCT03423173). To minimize the potential for confounding factors, we restricted the analysis to participants who were dengue seronegative at baseline (i.e., the reciprocal titer of dengue-neutralizing antibodies < 10 for all four serotypes).

RESULTS

Demographics and baseline characteristics

Overall, 702 baseline seronegative children and adolescents (aged 4–16 years) and 379 baseline seronegative adults (aged 18–60 years) were included in this analysis. Across the two studies, 50–53% of participants were female. Ethnicity was not recorded for the DEN-301 study, but race varied between the two studies, with the majority of participants in DEN-301 being Asian or American Indian/Alaska Native (85%) compared with White (79%) in DEN-304 (Table 1).

Comparison of geometric mean titers (GMTs) of dengue-neutralizing antibodies

To compare the immunogenicity of TAK-003 in recipients aged 4–16 years and those aged 18–60 years, GMTs of dengue-neutralizing antibodies assessed via microneutralization assay (MNT₅₀; expressed as the reciprocal of the dilution of test serum that shows a 50% reduction in plaque counts compared with that of virus controls) were calculated for each age group. Non-inferiority of GMTs was concluded for individual serotypes if the upper bound of the 95% confidence interval (CI) for the geometric mean ratio (GMR) between the two age groups was < 2.0.

As previously described in brief in Rivera et al.³³, the highest GMTs in both age groups were observed against DENV-2, with lower GMTs against the other three serotypes (Fig. 1). At month 4, non-inferiority of immunogenicity was concluded for DENV-1, DENV-2, and DENV-4, with the adult age group having lower GMTs against DENV-3 than the younger age group at this time point (128.9 vs. 228.0, respectively). By month 9, non-inferiority could be concluded for all four serotypes, with the highest GMTs against DENV-2, followed by DENV-1, DENV-3, and DENV-4.

Reverse cumulative distribution curves (RCDCs) of log₁₀ MNT₅₀ titer showed that, at month 4, a slightly higher proportion of adults had higher titers against DENV-1 and DENV-2 than children and adolescents in the DEN-301 study (Fig. 2). This trend was reversed for DENV-3, and for DENV-4 the RCDCs were similar for both age groups. By month 9, the same trends were still observed for DENV-1 and DENV-2, although less pronounced, and the titer distributions against DENV-3 and DENV-4 were the same for both age groups.

No clear differences or trends in GMTs were observed with increasing age within either study population (Fig. 3).

Table 1. Demographic and baseline characteristics of seronegative participants included in the immunobridging analysis.

	Age 4–16 years DEN-301 (N = 702)	Age 18–60 years DEN-304 (N = 379)
Age, mean (SD), years	8.5 (3.06)	41.2 (12.29)
Sex, n (%)		
Male	348 (49.6)	177 (46.7)
Female	354 (50.4)	202 (53.3)
Ethnicity, n (%)		
Hispanic or Latino	0 (0.0)	25 (6.6)
Not Hispanic or Latino	0 (0.0)	354 (93.4)
Unknown	702 (100.0)	0 (0.0)
Race		
American Indian or Alaska Native	296 (42.2)	2 (0.5)
Asian	300 (42.7)	2 (0.5)
Black or African American	61 (8.7)	71 (18.7)
Native Hawaiian/Pacific Island	0 (0.0)	1 (0.3)
White	22 (3.1)	299 (78.9)
Multiracial	23 (3.3)	4 (1.1)
Height, mean (SD), cm	129.4 (18.4)	171.8 (10.2)
Weight, mean (SD), kg	30.5 (14.0)	82.6 (15.7)
BMI, mean (SD), kg/m ²	17.3 (3.6)	27.9 (4.3)

BMI body mass index, SD standard deviation.

Seropositivity rates (i.e., the proportion of participants with post-vaccination reciprocal MNT₅₀ titers ≥ 10) were high for each age group at months 4 and 9, with seropositivity rates against individual serotypes ranging from 92% to 100% (Fig. 4).

Characterization of the immune response

A number of investigations of humoral immune responses to TAK-003 were performed for a subset of participants in each study (Table 2). Effective binding antibodies can prevent flavivirus infection by blocking virus attachment to the cell surface or virus neutralization, by interfering with membrane fusion, or via functional antiviral activities such as activation of Fc-dependent effector functions, including complement activation³⁴. TAK-003 assessment showed comparable total binding antibody levels directed against the whole virion between the age groups. Anti-viral binding antibodies constitute neutralizing antibodies and those with effector functions. TAK-003 elicits tetravalent neutralizing antibody responses in both the pediatric and adult population, with highest titers against DENV-2^{35–37}.

Evaluation of the proportion of type-specific neutralizing antibodies after DENV-2 depletion showed that TAK-003 elicits both type-specific and cross-reactive antibodies against DENV-1, DENV-3, and DENV-4 in both age groups³⁸. Additionally, complement-fixing antibodies were elicited against all four serotypes, and titers were of similar magnitudes across serotypes and age groups. In a separate study, antibodies produced following vaccination with TAK-003 were also functional in both activating the complement system and neutralizing infection by all DENV serotypes³⁹.

Evaluation of anti-dengue immunoglobulin G (IgG) avidity, a measure of the binding strength of induced antibodies, demonstrated that the tetravalent binding antibodies elicited by TAK-003 were affinity-matured in both age groups. This polyclonal




Fig. 1 GMRs of dengue-neutralizing antibodies. Adjusted GMRs (95% CI) of dengue-neutralizing antibodies reported for each serotype in baseline seronegative participants aged 4–16 years (DEN-301; Group A) vs. aged 18–60 years (DEN-304; Group B) (per protocol sets)³³. Abbreviations: CI confidence interval, DENV dengue virus, GMR geometric mean ratio, GMT geometric mean titer.

antibody maturation optimizes antibody affinity, resulting in increased neutralizing response⁴⁰.

Finally, TAK-003 also elicited anti-non-structural protein 1 (anti-NS1) antibody responses against the DENV-2 NS1 of the vaccine backbone, which was cross-reactive against NS1 from the other DENV serotypes, with similar magnitudes of responses across the two age groups. NS1 is a non-structural protein essential for viral replication and a viral toxin that can contribute to vascular leakage by initiating a cascade of endothelial layer hyperpermeabilization^{41–43}. NS1-specific antibodies induced by TAK-003 have been shown to block NS1-mediated endothelial hyper-permeabilization in vitro^{41,44}.

DISCUSSION

We demonstrate that neutralizing antibody responses are comparable in pediatric and adult vaccine recipients. The RCDs of dengue-neutralizing antibodies and seropositivity rates were similar, with over 95% of individuals achieving tetravalent seropositivity one month following vaccination, regardless of age group. Additionally, we observed comparable levels of antibody responses in various exploratory immunogenicity assessments. These findings suggest that the protective effect of TAK-003 in the adult population can be inferred from the clinical efficacy profile of TAK-003 from the pediatric population studied in the pivotal efficacy study (DEN-301).

The scientific principle of the applied analysis was to demonstrate similar levels of immune response elicited in both trial populations and thereby to infer similar levels of expected protection. TAK-003 elicits tetravalent neutralizing antibodies, which are important in protection against flavivirus infections and are generally regarded as the most relevant marker for protective immunity against DENV. Certain levels of neutralizing antibodies to yellow fever, Japanese encephalitis, or tick-borne encephalitis are widely accepted to correlate with protection^{45–47}. Neutralizing antibodies to dengue are also associated with a reduced risk of infection or severe disease caused by DENV⁴⁸.

The determination of DENV antibody CoPs is complicated by serological cross-reactivity among the four dengue serotypes. It is possible that CoP for each of the four serotypes could be different from one another. To date, a definite immunological CoP has not been established. However, analyses of neutralizing antibody responses elicited by TAK-003 indicate an association between a higher magnitude of neutralizing antibody titers and a lower risk of dengue³³.

While the neutralizing antibodies measured by MNT serve as a reproducible measure of immune response to TAK-003 for

comparison purposes, multiple components of the immune system likely contribute to protection elicited by vaccination with TAK-003. For instance, studies of immunity to the YF-17D vaccine, arguably one of the most efficacious vaccines, have demonstrated a broad range of immune responses elicited after vaccination that may contribute to protective immunity⁴⁹. Furthermore, immune mechanisms that prevent infection are not necessarily the same as the mechanisms that clear viral infections or restrict pathogenesis. While many viral vaccines block infection by eliciting functional antibodies, viral clearance, and recovery can also be mediated by cellular immune mechanisms⁵⁰. Even after serum antibody levels decline, memory B cells and T cells are maintained in the immune repertoire. Upon encountering the same pathogen, memory immune cells are reactivated to produce rapid and powerful recall responses^{51,52}. Thus, a broad range of immune responses encompassing multiple arms of the immune system may contribute to the prevention and clearance of viral infections. We broadly characterized the immune responses elicited by TAK-003 in the context of previously established principles of antiviral immunity, flavivirus immunity, and vaccine correlates of protection⁵³, including neutralizing antibodies (type-specific and cross-reactive), binding antibodies, complement-fixing antibodies, poly-clonal antibody avidity, and antibody response to NS1. TAK-003 elicited comparable levels of antibody responses across a wide age range of vaccine recipients across the two phase 3 studies.

Dengue exposure increases with age in endemic areas and is known to positively influence subsequent immune response, both in magnitude and quality. The use of baseline seronegative participants for this analysis was considered appropriate because it ensures that the two populations are comparable, except for the age factor. In dengue-endemic countries, there are practical constraints in screening and enrolling seronegative adult participants. Similarly, enrolling children in non-dengue-endemic countries in a study using an experimental vaccine presents practical difficulties. To address the above-mentioned challenges, it was determined that a comparison of the TAK-003 arms from two separate trials would be a reasonable approach. Additionally, we assumed that vaccine efficacy in the baseline seropositive population will at least be like that in baseline seronegative participants. This is supported by the efficacy data in the pivotal trial and is therefore realistic. Besides, the seropositive group is immunologically heterogeneous due to the type and number of past dengue exposures. This limits any meaningful comparison on immunobridging studies in that population.

The World Health Organization (WHO) guidance on dengue vaccine development recommends careful evaluation of the scientific arguments for and against extrapolation of the efficacy




Fig. 2 RCDCs of dengue-neutralizing antibodies. RCDCs of dengue-neutralizing antibodies reported for each serotype at (a) month 4, and (b) month 9 in baseline seronegative participants aged 4–16 years (DEN-301) vs. 18–60 years (DEN-304) (per protocol sets). Abbreviations: DENV dengue virus, MNT₅₀ microneutralization titer assay resulting in 50% reduction in plaque counts compared with that of virus controls, RCDC reverse cumulative distribution curve.

results between populations that differ in a specific characteristic. In that context, this analysis did not suggest any evidence of lower immune response in adults than in children. Exploratory subgroup analysis in the pivotal efficacy trial has also not indicated any evidence of potentially lower efficacy with higher age³³.

Throughout the clinical development program, we have noted considerable inter-participant variability in the immune response to TAK-003 measured in the neutralizing assay. Therefore, we selected a non-inferiority margin of 0.5/2.0 for statistical comparison, as used to assess lot-to-lot consistency in the DEN-304 study.

In the context of dengue vaccine development, there is an emphasis on measuring antibody response away from the time of vaccination. This is relevant in the context of TAK-003, which has a DENV-2 backbone and so elicits a dominant immunological response, implying the possibility of cross-reactivity. While month 4 was chosen to capture the peak of the immunological response

to TAK-003 in accordance with a typical time point for immunogenicity assessment in the clinical development program, we also assessed immunobridging at month 9. It was reassuring to see that immune responses at that time point were statistically comparable, indicating similar longer-term immunogenicity, overall.

We would like to highlight some of the limitations of this analysis. Immunobridging analysis was not intended at the time each trial was designed, hence data were not collected concurrently. Additionally, no sample size calculation was performed, and all eligible participants in the respective studies were included. We did not present any data on cell-mediated responses because they were not investigated in either of these two trials, but have been evaluated in other trials in the clinical development program. Nonetheless, we believe that none of the above undermine the analysis's conclusions.




Fig. 3 GMTs of MNT₅₀ dengue-neutralizing antibodies. GMTs (95% CI) of MNT₅₀ dengue-neutralizing antibodies reported for each serotype by age group in baseline seronegative participants (per protocol sets). Abbreviations: CI confidence interval, DENV dengue virus, GMT geometric mean titer, MNT₅₀ microneutralization titer assay resulting in 50% reduction in plaque counts compared with that of virus controls.

While the peak of dengue transmission varies by country and endemicity, dengue is a significant health problem for adults in all dengue-endemic countries, as well as adult travelers to these locations. It is likely that dengue control will require a multimodal approach, with vaccination playing a significant role at some stage. Additionally, large-scale community immunization initiatives will be required to have a substantial impact, and they must consider all affected age groups.

In summary, immunobridging can be regarded as a reasonable alternative to practically difficult placebo-controlled efficacy trials in dengue-naïve adults in the context of the development of a dengue vaccine. The present analysis shows biologically comparable TAK-003 immune response in seronegative adults as in the pediatric population and may therefore be used to infer comparable vaccine protective effects in both adult and pediatric populations.

METHODS

Studies included

DEN-301 was a large-scale efficacy study performed in healthy children aged 4–16 years living in regions of Asia and Latin America considered endemic for dengue (NCT02747927). Participants were randomized 2:1, stratified by age category and region, to receive a two-dose schedule of TAK-003 or placebo, administered 3 months apart. Full details of the study design and inclusion criteria have been published previously⁵⁴. The study is currently ongoing and has recently completed the fourth year of safety and efficacy follow-up.

DEN-304 was designed as a lot-to-lot consistency study in adults aged 18–60 years living in parts of the United States considered non-endemic for dengue (NCT03423173). Participants were randomized 1:1:1 to receive one of three lots of the two-dose TAK-003 formulation, or placebo, administered 3 months apart.

Both trials were conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation Tripartite Guidelines for Good Clinical Practice, as well as in accordance with applicable local regulations. Informed assent or consent forms and the trial protocol and its amendments were reviewed and approved by institutional review boards (IRBs), independent ethics committees (IECs), and health authorities. Details of IRBs and IECs are outlined in Table S1. Written informed assent or consent was obtained from all participants (or their parents or legal guardians) before enrollment.

Immunogenicity measures

Immunogenicity was assessed in terms of GMTs of dengue-neutralizing antibodies, as measured by a dengue microneutralization titer assay resulting in $\geq 50\%$ reduction in titer (MNT₅₀). The validated MNT₅₀ assay used in these studies is in accordance with the WHO guidance on the evaluation of dengue vaccine immunogenicity⁵⁵. The immunogenicity of the vaccine was also assessed in terms of seropositivity to each serotype, with seropositive being defined as a reciprocal MNT₅₀ titer ≥ 10 . Pre-existing seropositivity was evaluated at baseline, with only participants who were seronegative (i.e., MNT₅₀ < 10 for all serotypes) included in this analysis. Only seronegative TAK-003 participants were included to standardize the population across regions and because it was assumed, based on evidence from the clinical development program, that vaccine efficacy was at least as high in baseline seropositive as seronegative participants^{33,36,54,56}. For the current analysis, as previously presented briefly in Rivera et al.³³, comparisons of GMTs and seropositivity between participants in the two studies were performed at months 4 and 9 (i.e., one and six months after receipt of the second dose of TAK-003).




Fig. 4 Seropositivity rates for each dengue serotype. Seropositivity rates (95% CI) reported for each dengue serotype in baseline seronegative participants aged 4–16 years (DEN-301) and aged 18–60 years (DEN-304). Abbreviations: CI confidence interval, DENV dengue virus.

Exploratory immunology analysis

Exploratory immunology analyses were performed on a subset of 48 seronegative participants from each study. This subset was selected from participants who consented for their samples to be used for future research and was based on the availability of a sufficient volume ($\geq 500 \mu\text{L}$) of serum from both pre- and postvaccination time points. Participants with virologically confirmed or asymptomatic dengue were excluded if they were positive for polymerase chain reaction or non-NS1 positive, or showed a four-fold rise in MNT titers for any serotype. For the DENV-2 and reporter virus particle (RVP) assay to assess type-specific neutralizing antibody response, samples were further selected with a minimum tetravalent MNT_{50} of 20 being required for inclusion.

To understand the immune response profile in seronegative adults, representative of travelers from non-endemic areas, we characterized the spectrum of immune responses elicited by TAK-003 using samples from DEN-304 collected on days 1, 120, and 270 from 48 baseline seronegative participants, who were randomly selected from the group vaccinated with TAK-003 Lot 3 (Group 3), using a number of non-GxP exploratory assessments. The analysis population for the primary immunobridging evaluation was restricted to baseline seronegative participants to minimize the influence of confounding factors.

Full methodologies for all the exploratory immunology assessments have been published previously. Geometric mean concentrations of anti-DENV NS1 were evaluated using the methods previously described in full in Sharma et al., 2020⁴¹. Briefly, 96-well microtiter plates were coated with DENV NS1 (1.0 $\mu\text{g}/\text{mL}$) in carbonate/bicarbonate buffer pH 9.6 overnight at 4 °C. Following washing (phosphate buffered saline-tween (PBS-T)) and blocking (SuperBlock T20 PBS Blocking Buffer) steps, serum samples were added, and the plates incubated with horseradish peroxidase-conjugated goat anti-human IgG-gamma chain. After washing, color was developed with ABTS Peroxidase Substrate, stopped with 1 \times ABTS Peroxidase Stop Solution, and optical density at 405 nm measured using a Spectramax 384 Plus plate reader. The concentration of anti-DENV NS1 IgG in serum samples was determined relative to the reference standard and expressed in relative units/mL (RU/mL).

Antibody avidity was measured using Octet HTX systems, as described in Tsuji et al., 2021⁴⁰. Briefly, anti-dengue polyclonal IgG (125 $\mu\text{g}/\text{mL}$) in 0.1% bovine serum albumin (BSA)-PBST were purified from serum by Protein G Sepharose and bound to the biotinylated Viral-like particle (VLP)-captured high-precision streptavidin biosensor for 1800 seconds. The sensor was then incubated with dissociation buffer (0.1% BSA-PBST, 0.35 M NaCl) for 1200 seconds.

Anti-dengue complement-fixing antibody titers were assessed using the Luminex assay, as described in full in Nascimento et al., 2021⁵⁷. Briefly, VLP-coupled microspheres at 25 microspheres/ μL were incubated with serum samples for 1 hour and washed with PBS-T, 50 $\mu\text{L}/\text{well}$ of plasma-derived purified human C1q at 4 $\mu\text{g}/\text{mL}$ added and then incubated for 30 minutes. Following PBS-T washes, 50 $\mu\text{L}/\text{well}$ of a polyclonal sheep IgG anti-human C1q at 6.4 $\mu\text{g}/\text{mL}$ was added and incubated for 30 minutes. After two additional PBS-T washes, the microspheres were incubated with 50 $\mu\text{L}/\text{well}$ of an anti-sheep IgG conjugated to phycoerythrin at 10 $\mu\text{g}/\text{mL}$ for 30 minutes. The microspheres were washed with PBS-T, reconstituted with assay buffer, and read on a Luminex plate reader (Magpix or FlexMap 3D). Anti-dengue virus complement-fixing antibody concentrations were calculated relative to a reference standard.

Dengue total binding IgG concentrations were assessed using a dengue-specific sandwich (capture) IgG ELISA previously used in Michlmayr et al., 2021⁵⁸. Briefly, 96-well microtiter plates were coated with pan-flavivirus 4G2 monoclonal antibody (1.0 $\mu\text{g}/\text{mL}$) in carbonate/bicarbonate buffer pH 9.6 overnight at 4 °C. Following washing with PBS-T and blocking (SuperBlock T20 PBS Blocking Buffer) steps, monovalent dengue vaccine drug substance was added, followed by serum samples, and the plates were incubated with horseradish peroxidase-conjugated goat anti-human IgG-gamma chain. After washing, color was developed with ABTS Peroxidase Substrate, stopped with 1 \times ABTS Peroxidase Stop Solution, and optical density at 405 nm measured using a Spectramax 384 Plus plate reader. The concentration of anti-dengue binding antibodies in serum samples was determined relative to the reference standard and expressed in relative units/mL (RU/mL).

Table 2. Exploratory immunology assessments and readouts for each serotype.

Measure	Time point	Age group	DENV-1	DENV-2	DENV-3	DENV-4
Anti-dengue NS1 IgG concentration (EU/mL)	Month 4	4–16 years	245.7 (213.0, 283.6)	1,053.0 (882.2, 1,256.8)	219.2 (189.8, 253.3)	178.7 (149.5, 213.7)
		18–60 years	299.2 (232.8, 384.4)	1,299.9 (1,032.1, 1,637.1)	210.3 (157.8, 280.4)	144.1 (106.0, 196.0)
	Month 9	4–16 years	140.8 (118.3, 167.7)	365.5 (303.4, 440.2)	101.4 (88.3, 116.4)	85.8 (73.0, 100.8)
Dengue total binding IgG concentrations (RU/mL)		18–60 years	185.3 (146.6, 234.2)	624.5 (494.3, 789.0)	114.3 (87.6, 149.2)	83.8 (64.1, 109.7)
	Month 4	4–16 years	1,165.8 (937.6, 1,449.6)	1,292.0 (1,060.7, 1,573.7)	1,414.4 (1,180.2, 1,695.1)	641.3 (528.5, 778.1)
		18–60 years	1,056.9 (826.3, 1,352.0)	1,263.5 (1,005.8, 1,587.1)	951.3 (774.4, 1,168.5)	469.9 (370.5, 596.0)
Anti-dengue complement antibody titers (EU/mL)	Month 9	4–16 years	735.2 (579.8, 932.2)	894.3 (710.2, 1,126.1)	835.4 (670.6, 1,040.8)	465.4 (370.9, 583.9)
		18–60 years	723.6 (544.7, 961.3)	844.3 (653.2, 1,091.1)	610.5 (486.4, 766.2)	329.5 (257.3, 421.9)
	Month 4	4–16 years	36.8 (27.9, 48.7)	31.6 (24.4, 40.8)	33.6 (25.7, 43.9)	12.7 (9.5, 16.9)
Anti-dengue IgG avidity (nm*s)		18–60 years	25.3 (18.8, 34.0)	24.5 (19.0, 31.7)	19.3 (14.3, 26.1)	9.6 (7.3, 12.6)
	Month 9	4–16 years	17.1 (11.6, 25.0)	15.3 (10.8, 21.6)	13.3 (9.0, 19.8)	6.4 (4.5, 8.9)
		18–60 years	14.7 (10.4, 20.8)	13.1 (9.5, 18.1)	9.6 (6.8, 13.6)	5.9 (4.3, 8.0)
Anti-dengue IgG avidity (nm*s)	Month 4	4–16 years	526.7 (300.4, 923.6)	424.2 (225.8, 796.7)	307.2 (161.5, 584.6)	147.3 (70.4, 307.8)
		18–60 years	796.7 (433.3, 1,464.9)	813.4 (466.5, 1,418.1)	403.8 (217.5, 749.8)	224.2 (105.4, 477.0)
	Month 9	4–16 years	222.8 (98.6, 503.8)	315.0 (146.2, 679.0)	92.8 (37.9, 227.3)	35.1 (13.6, 91.1)
Percent of type-specific neutralizing antibody response/EC₅₀ (RVP) after DENV-2 nAb depletion (%)		18–60 years	829.3 (477.7, 1,439.6)	931.7 (629.8, 1,378.4)	330.5 (163.7, 667.4)	108.8 (42.6, 278.0)
	Month 4	4–16 years	47.4 (31.0, 64.2)	DeMaso et al. ³⁸	57.1 (39.4, 73.7)	94.4 (81.3, 99.3)
		18–60 years	68.0 (46.5, 85.1)	DeMaso et al. ³⁸	72.2 (46.5, 90.3)	91.3 (72.0, 98.9)
Percent of type-specific neutralizing antibody response/EC₅₀ (RVP) after DENV-2 nAb depletion (%)	Month 9	4–16 years	20.0 (5.7, 43.7)	DeMaso et al. ³⁸	47.1 (23.0, 72.2)	100.0 (83.2, 100.0)
		18–60 years	76.2 (52.8, 91.8)	DeMaso et al. ³⁸	37.5 (15.2, 64.6)	94.4 (72.7, 99.9)

CI confidence interval, DENV dengue virus, EC₅₀ 50% effective concentration, EU/mL effective units per milliliter, IgG immunoglobulin G, nAb neutralizing antibody, NS1 nonstructural protein 1, RU/mL relative units per milliliter, RVP reporter virus particle.

Summary of exploratory immunology assessments and readouts for each serotype in participants aged 4–16 years (DEN-301) vs. aged 18–60 years (DEN-304). Data are presented as geometric means (95% CIs) unless otherwise stated. A total of 48 participants were included in the analysis in each study.

As studies have shown that TAK-003 induces higher neutralizing antibody titers against DENV-2 than the other serotypes^{33,36,54,56}, together with the presence of DENV-2 type-specific neutralizing antibodies in post-vaccination samples⁵⁹, type-specific neutralizing antibody responses against DENV-1, -3, and -4 were evaluated using DENV-2 depletion and RVP assay, as described in DeMaso et al.³⁸. Briefly, Tosyl-activated Dynabeads coupled with pan-flavivirus 4G2 monoclonal antibody were bound with either live DENV-2 or BSA control, blocked with BSA, and incubated with heat-inactivated vaccine-recipient sera to deplete DENV-2 targeting antibodies. Depletion was repeated 6 times and remaining neutralizing antibodies were quantified using an RVP neutralization assay. The RVPs were incubated with serial dilutions of DENV-2-depleted vaccine-recipient sera. Raji DC-SIGN cells were infected with these immune complexes and the luciferase readout measured 72 hours post infection. Results were reported as half-maximal effective concentration (EC₅₀), the reciprocal dilution of serum required to neutralize 50% of the input RVP, for each serotype after mock or DENV-2 depletion.

Statistical analysis

Differences in GMTs for each of the four dengue serotypes between the 4- to 16-years age group (DEN-301; Group A) and the 18- to 60-years group (DEN-304; Group B) were estimated using an analysis of (co)variance model with natural logarithms of titers as a response variable and covariates including natural logarithm of baseline titer, and interaction terms. Mean titers, mean differences, and 95% CIs for the difference were anti-log-transformed to obtain group GMTs, between-group GMRs, and 95% CIs for the ratio.

For the primary post-hoc comparison based on GMT data at month 4 (one-month postsecond vaccine dose), non-inferiority was concluded for a given serotype if the upper bound of the respective 95% CI for the GMR between the two studies was below 2.0. Overall noninferiority of immune response was formally concluded if non-inferiority was shown for all four serotypes, therefore no multiplicity adjustment was applied.

No statistical hypotheses were tested in the exploratory immunology analysis; data are presented as GMTs or geometric mean concentrations, as appropriate, plus corresponding 95% CIs. Ninety-five percent CIs were calculated by the Clopper-Pearson method for serotype specificity and using t-distribution critical values for avidity measures. All analysis was performed using SAS version 9.2 or higher.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY

The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting the results of the completed studies, will be made available within three months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymization. Data requests should follow the process described in the Data Sharing section on <https://clinicaltrials.takeda.com/> and <https://vivli.org/ourmember/takeda/>.

Received: 2 September 2022; Accepted: 10 May 2023;

Published online: 25 May 2023

REFERENCES

- Kempf, L., Goldsmith, J. C. & Temple, R. Challenges of developing and conducting clinical trials in rare disorders. *Am. J. Med. Genet. Part A* **176**, 773–783 (2018).
- Luxi, N. et al. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. *Drug Saf.* **44**, 1247–1269 (2021).
- Fink, D. WHO meeting on COVID-19 vaccines research: Immunobridging to evaluate vaccines. Vol. 2022 (2021).
- Fritzell, B. Bridging studies. *Dev. Biol. Stand* **95**, 181–188 (1998).
- World Health Organization. Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations. Vol. 2022 (2017).
- Essink, B. et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥ 18 Years. *Clin. Infect. Dis.* **75**, 390–398 (2022).
- US Food & Drug Administration: Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document: Licensure and Emergency Use Authorization of Vaccines to Prevent COVID-19 for Use in Pediatric Populations. 2022 (2021).
- Lowy, D., Herrero, R. & Hildesheim, A. Chapter 1. Summary of IARC/NCI Expert Meeting on Primary End-points for Prophylactic HPV Vaccine Trials. in *IARC HPV Working Group. Primary End-points for Prophylactic HPV Vaccine Trials* (International Agency for Research on Cancer, Lyon, France, 2014).
- Black, S. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. *Pediatr. Infect. Dis. J.* **19**, 187–195 (2000).
- Eskola, J. et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. *N. Engl. J. Med.* **344**, 403–409 (2001).
- O'Brien, K. L. et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. *Lancet* **362**, 355–361 (2003).
- Vesikari, T. et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. *Pediatr. Infect. Dis. J.* **28**, S66–S76 (2009).
- Yeh, S. H. et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. *Pediatrics* **126**, e493–e505 (2010).
- Bonten, M. J. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N. Engl. J. Med.* **372**, 1114–1125 (2015).
- Palmu, A. A. et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. *Lancet* **381**, 214–222 (2013).
- FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N. Engl. J. Med.* **356**, 1915–1927 (2007).
- Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* **367**, 1247–1255 (2006).
- Puthanakit, T. et al. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. *J. Infect. Dis.* **214**, 525–536 (2016).
- Munoz, N. et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. *Lancet* **373**, 1949–1957 (2009).
- Block, S. L. et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. *Pediatrics* **118**, 2135–2145 (2006).
- Giuliano, A. R. et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)-The MAM Study. *Vaccine* **33**, 5640–5646 (2015).
- Giuliano, A. R. et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N. Engl. J. Med.* **364**, 401–411 (2011).
- Huh, W. K. et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. *Lancet* **390**, 2143–2159 (2017).
- European Centre for Disease Prevention and Control. Dengue factsheet. Vol. 2022 (2021).
- Tantawichien, T. Dengue fever and dengue haemorrhagic fever in adolescents and adults. *Paediatr. Int. Child Health* **32**, 22–27 (2012).
- Wilder-Smith, A. Dengue infections in travellers. *Paediatr. Int. Child Health* **32**, 28–32 (2012).
- Pang, J., Hsu, J. P., Yeo, T. W., Leo, Y. S. & Lye, D. C. Diabetes, cardiac disorders and asthma as risk factors for severe organ involvement among adult dengue patients: A matched case-control study. *Sci. Rep.* **7**, 39872 (2017).
- Toledo, J. et al. Relevance of Non-communicable Comorbidities for the Development of the Severe Forms of Dengue: A Systematic Literature Review. *PLoS Negl. Trop. Dis.* **10**, e0004284 (2016).
- Watanaveeradej, V. et al. Transplacentally transferred maternal-infant antibodies to dengue virus. *Am. J. Trop. Med. Hyg.* **69**, 123–128 (2003).

30. Halstead, S. B. Neutralization and antibody-dependent enhancement of dengue viruses. *Adv. Virus Res.* **60**, 421–467 (2003).
31. Gilbert, P. B. et al. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. *Am. J. Trop. Med. Hyg.* **101**, 164–179 (2019).
32. Huang, Y. et al. Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries. *Trans. R. Soc. Trop. Med. Hyg.* **115**, 750–763 (2021).
33. Rivera, L. et al. Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003). *Clin. Infect. Dis.* **75**, 107–117 (2022).
34. Pierson, T. C. & Diamond, M. S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. *Expert Rev. Mol. Med.* **10**, e12 (2008).
35. Tricou, V. et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. *Lancet* **395**, 1434–1443 (2020).
36. Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial. *Lancet* **395**, 1423–1433 (2020).
37. Tricou, V. et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. *Vaccine* **38**, 1513–1519 (2020).
38. DeMaso, C. et al. Specificity and Breadth of the Neutralizing Antibody Response to a Live Attenuated Tetravalent Dengue Vaccine. *J. Infect. Dis.* **226**, 1959–1963 (2022).
39. Nascimento, E. J. M. et al. Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine are Functional in Activating the Complement System. *J. Infect. Dis.* [jiac476](https://doi.org/10.1093/infdis/jiac476), <https://doi.org/10.1093/infdis/jiac476> (2022).
40. Tsuji, I., Dominguez, D., Egan, M. A. & Dean, H. J. Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine. *J. Infect. Dis.* **225**, 1533–1544 (2022).
41. Sharma, M. et al. Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate. *J. Infect. Dis.* **221**, 867–877 (2020).
42. Jayathilaka, D. et al. Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection. *Nat. Commun.* **9**, 5242 (2018).
43. Lin, C. F. et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. *J. Med. Virol.* **69**, 82–90 (2003).
44. Tricou, V. et al. Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting. *Vaccine* **40**, 1143–1151 (2022).
45. Hombach, J., Solomon, T., Kurane, I., Jacobson, J. & Wood, D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. *Vaccine* **23**, 5205–5211 (2005).
46. Kreil, T. R., Burger, I., Bachmann, M., Fraiss, S. & Eibl, M. M. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. *Clin. Exp. Immunol.* **110**, 358–361 (1997).
47. Mason, R. A., Tauraso, N. M., Spertzel, R. O. & Ginn, R. K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. *Appl. Microbiol.* **25**, 539–544 (1973).
48. Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. *Proc. Natl Acad. Sci. USA* **113**, 728–733 (2016).
49. Pulendran, B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. *Nat. Rev. Immunol.* **9**, 741–747 (2009).
50. Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. *Clin. Infect. Dis.* **47**, 401–409 (2008).
51. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. *Science* **272**, 54–60 (1996).
52. Berard, M. & Tough, D. F. Qualitative differences between naïve and memory T cells. *Immunology* **106**, 127–138 (2002).
53. Plotkin, S. A. Correlates of protection induced by vaccination. *Clin. Vaccin. Immunol.* **17**, 1055–1065 (2010).
54. Biswal, S. et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. *N. Engl. J. Med.* **381**, 2009–2019 (2019).
55. Roehrig, J. T., Hombach, J. & Barrett, A. D. Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. *Viral Immunol.* **21**, 123–132 (2008).
56. Lopez-Medina, E. et al. Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. *J. Infect. Dis.* **225**, 1521–1532 (2022).
57. Nascimento, E. J. M. et al. Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus. *Int. J. Mol. Sci.* **22**, 12004 (2021).
58. Michlmayr, D. et al. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. *J. Infect. Dis.* **223**, 247–257 (2021).
59. Swanstrom, J. A. et al. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate. *J. Infect. Dis.* **217**, 1932–1941 (2018).

ACKNOWLEDGEMENTS

This study was funded by Takeda Pharmaceuticals. Under direction of the authors, Jenny Engelman (Excel Medical Affairs) provided writing assistance for this manuscript. Editorial assistance in formatting, proof-reading, and copy-editing was provided by Excel Medical Affairs. Takeda Pharmaceuticals provided funding to Excel Medical Affairs for support in writing and editing this manuscript. The interpretation of the data was made by the authors independently.

AUTHOR CONTRIBUTIONS

L.B., E.L.M., E.D.M., L.T. and V.W. were trial investigators. S.B. and V.T. led the clinical trials. I.L. designed the immunobridging approach and analysis; S.B., N.F. and I.L. interpreted the results. M.S. led the exploratory immunocharacterization assessments and N.F. performed the statistical analysis of those results. M.S., V.T., N.F. and S.B. planned the analysis and interpreted the results of the exploratory immunocharacterization data. All of the authors contributed to the concept of the manuscript, reviewed and provided critical comments in various stages of manuscript development. SB managed the publication. I.L. and L.B. contributed equally to this publication.

COMPETING INTERESTS

IL, NF, FN, MS, VT, and SB are employees of Takeda and hold stock/stock options in Takeda. LMT, VW, and PJW have no disclosures to make. EDM Jr and LB have participated in an advisory board for Takeda.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41541-023-00670-6>.

Correspondence and requests for materials should be addressed to Shibadas Biswal.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023